These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 20035611)

  • 61. Pharmacokinetics of meropenem in critically ill patients with severe infections.
    Binder L; Schwörer H; Hoppe S; Streit F; Neumann S; Beckmann A; Wachter R; Oellerich M; Walson PD
    Ther Drug Monit; 2013 Feb; 35(1):63-70. PubMed ID: 23318279
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Aminoglycoside extended interval dosing in neonates is safe and effective: a meta-analysis.
    Nestaas E; Bangstad HJ; Sandvik L; Wathne KO
    Arch Dis Child Fetal Neonatal Ed; 2005 Jul; 90(4):F294-300. PubMed ID: 15857879
    [TBL] [Abstract][Full Text] [Related]  

  • 63. How to optimize antibiotic pharmacokinetic/pharmacodynamics for Gram-negative infections in critically ill patients.
    Heffernan AJ; Sime FB; Taccone FS; Roberts JA
    Curr Opin Infect Dis; 2018 Dec; 31(6):555-565. PubMed ID: 30299354
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Outcome of patients treated by an aminoglycoside pharmacokinetic dosing service.
    Sveska KJ; Roffe BD; Solomon DK; Hoffmann RP
    Am J Hosp Pharm; 1985 Nov; 42(11):2472-8. PubMed ID: 4073064
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The impact of variation in renal replacement therapy settings on piperacillin, meropenem, and vancomycin drug clearance in the critically ill: an analysis of published literature and dosing regimens*.
    Jamal JA; Udy AA; Lipman J; Roberts JA
    Crit Care Med; 2014 Jul; 42(7):1640-50. PubMed ID: 24674926
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Considerations for higher doses of daptomycin in critically ill patients with methicillin-resistant Staphylococcus aureus bacteremia.
    Falcone M; Russo A; Venditti M; Novelli A; Pai MP
    Clin Infect Dis; 2013 Dec; 57(11):1568-76. PubMed ID: 24046298
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Comment: once-daily aminoglycoside dosing in critically ill patients.
    Wolfe TA; Dasta JF
    Ann Pharmacother; 1998 Oct; 32(10):1109-10. PubMed ID: 9793609
    [No Abstract]   [Full Text] [Related]  

  • 68. Optimization of dosing regimens and dosing in special populations.
    Sime FB; Roberts MS; Roberts JA
    Clin Microbiol Infect; 2015 Oct; 21(10):886-93. PubMed ID: 25980350
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Which reliable pharmacodynamic breakpoint should be advised for ciprofloxacin monotherapy in the hospital setting? A TDM-based retrospective perspective.
    Pea F; Poz D; Viale P; Pavan F; Furlanut M
    J Antimicrob Chemother; 2006 Aug; 58(2):380-6. PubMed ID: 16735422
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Pharmacokinetic analysis of piperacillin administered with tazobactam in critically ill, morbidly obese surgical patients.
    Sturm AW; Allen N; Rafferty KD; Fish DN; Toschlog E; Newell M; Waibel B
    Pharmacotherapy; 2014 Jan; 34(1):28-35. PubMed ID: 23864417
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Flucloxacillin dosing in critically ill patients with hypoalbuminaemia: special emphasis on unbound pharmacokinetics.
    Ulldemolins M; Roberts JA; Wallis SC; Rello J; Lipman J
    J Antimicrob Chemother; 2010 Aug; 65(8):1771-8. PubMed ID: 20530507
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Optimisation of antimicrobial dosing based on pharmacokinetic and pharmacodynamic principles.
    Hoo GSR; Liew YX; Kwa AL
    Indian J Med Microbiol; 2017; 35(3):340-346. PubMed ID: 29063877
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Serum aminoglycoside clearance is predicted as poorly by renal aminoglycoside clearance as by creatinine clearance in critically ill patients.
    Hickling KG; Begg EJ; Perry RE; Atkinson HC; Sharman JR
    Crit Care Med; 1991 Aug; 19(8):1041-7. PubMed ID: 1860329
    [TBL] [Abstract][Full Text] [Related]  

  • 74. What is the relevance of fosfomycin pharmacokinetics in the treatment of serious infections in critically ill patients? A systematic review.
    Parker S; Lipman J; Koulenti D; Dimopoulos G; Roberts JA
    Int J Antimicrob Agents; 2013 Oct; 42(4):289-93. PubMed ID: 23880170
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Piperacillin penetration into tissue of critically ill patients with sepsis--bolus versus continuous administration?
    Roberts JA; Roberts MS; Robertson TA; Dalley AJ; Lipman J
    Crit Care Med; 2009 Mar; 37(3):926-33. PubMed ID: 19237898
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Current use of aminoglycosides: indications, pharmacokinetics and monitoring for toxicity.
    Avent ML; Rogers BA; Cheng AC; Paterson DL
    Intern Med J; 2011 Jun; 41(6):441-9. PubMed ID: 21309997
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Pharmacokinetic changes and dosing modification of aminoglycosides in critically ill obese patients: a literature review.
    Velissaris D; Karamouzos V; Marangos M; Pierrakos C; Karanikolas M
    J Clin Med Res; 2014 Aug; 6(4):227-33. PubMed ID: 24883145
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Administration of higher doses of amikacin in early stages of sepsis in critically ill patients.
    Najmeddin F; Ahmadi A; Mahmoudi L; Sadeghi K; Khalili H; Ahmadvand A; Najafi A; Mojtahedzadeh M
    Acta Med Iran; 2014; 52(9):703-9. PubMed ID: 25325208
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The antimicrobial therapy puzzle: could pharmacokinetic-pharmacodynamic relationships be helpful in addressing the issue of appropriate pneumonia treatment in critically ill patients?
    Pea F; Viale P
    Clin Infect Dis; 2006 Jun; 42(12):1764-71. PubMed ID: 16705585
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Pharmacokinetics of meropenem in critically ill patients receiving continuous venovenous haemofiltration: a randomised controlled trial of continuous infusion versus intermittent bolus administration.
    Jamal JA; Mat-Nor MB; Mohamad-Nor FS; Udy AA; Wallis SC; Lipman J; Roberts JA
    Int J Antimicrob Agents; 2015 Jan; 45(1):41-5. PubMed ID: 25455853
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.